Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead program CALY-002 to treat eosinophilic esophagitis (EoE).

Gilde Healthcare Partners and INKEF Capital led the round, announced Feb. 20, with participation from M Ventures, and Johnson & Johnson Development Corp. - JJDC Inc. Calypso has received the first tranche of undisclosed size, co-founder and CEO Alain Vicari told BioCentury; he declined to disclose terms regarding the balance. ...